SF3B1 mutations in chronic lymphocytic leukemia.

SF3B1 is a critical component of the splicing machinery, which catalyzes the removal of introns from precursor messenger RNA (mRNA). Next-generation sequencing studies have identified mutations in SF3B1 in chronic lymphocytic leukemia (CLL) at high frequency. In CLL, SF3B1 mutation is associated with more aggressive disease and shorter survival, and recent studies suggest that it can be incorporated into prognostic schema to improve the prediction of disease progression. Mutations in SF3B1 are predominantly subclonal genetic events in CLL, and hence are likely later events in the progression of CLL. Evidence of altered pre-mRNA splicing has been detected in CLL cases with SF3B1 mutations. Although the causative link between SF3B1 mutation and CLL pathogenesis remains unclear, several lines of evidence suggest SF3B1 mutation might be linked to genomic stability and epigenetic modification.

[1]  Peter J Campbell,et al.  Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms , 2011, Blood.

[2]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[3]  C. Will,et al.  The Spliceosome: Design Principles of a Dynamic RNP Machine , 2009, Cell.

[4]  T. Komori,et al.  Mammalian polycomb-mediated repression of Hox genes requires the essential spliceosomal protein Sf3b1. , 2005, Genes & development.

[5]  A. Rosenwald,et al.  Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL. , 2008, Blood.

[6]  A. Jankowska,et al.  SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. , 2012, Blood.

[7]  G. Garcia-Manero,et al.  SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. , 2012, Blood.

[8]  A. Sivachenko,et al.  SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. , 2011, The New England journal of medicine.

[9]  R. Foà,et al.  Analysis of SF3B1 mutations in monoclonal B‐cell lymphocytosis , 2013, Hematological oncology.

[10]  A. McKenna,et al.  Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.

[11]  M. Cazzola,et al.  Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. , 2012, Blood.

[12]  R. Wollman,et al.  A genome-wide siRNA screen reveals diverse cellular processes and pathways that mediate genome stability. , 2009, Molecular cell.

[13]  N. Chiorazzi,et al.  mechanisms of disease Chronic Lymphocytic Leukemia , 2010 .

[14]  Bjoern Sander,et al.  Major conformational change in the complex SF3b upon integration into the spliceosomal U11/U12 di-snRNP as revealed by electron cryomicroscopy. , 2005, Molecular cell.

[15]  J. Valcárcel,et al.  Frequent somatic mutations in components of the RNA processing machinery in chronic lymphocytic leukemia , 2013, Leukemia.

[16]  A. Bowcock,et al.  Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma , 2013, Nature Genetics.

[17]  Bjoern Sander,et al.  Molecular Architecture of the Multiprotein Splicing Factor SF3b , 2003, Science.

[18]  J. Carpten,et al.  Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. , 2012, Blood.

[19]  Kenric Leung,et al.  The Life History of 21 Breast Cancers , 2015, Cell.

[20]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[21]  Li Ding,et al.  RECURRENT MUTATIONS IN THE U2AF1 SPLICING FACTOR IN MYELODYSPLASTIC SYNDROMES , 2011, Nature Genetics.

[22]  D. Catovsky,et al.  The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. , 2013, Blood.

[23]  T. Stankovic,et al.  SF3B1 Mutations in CLL Are Equivalent to p53/ATM Dysfunction and Cause Defective Puma Upregulation in Response to Chemotherapy , 2012 .

[24]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[25]  Catherine J. Wu.  CLL clonal heterogeneity: an ecology of competing subpopulations. , 2012, Blood.

[26]  M. Cazzola,et al.  Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms. , 2013, Blood.

[27]  Lincoln D. Stein,et al.  Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes , 2012, Nature.

[28]  Frequent Pathway Mutations of Splicing Machinery in Myelodysplasia , 2011 .

[29]  A. Jankowska,et al.  Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. , 2012, Blood.

[30]  Alfonso Valencia,et al.  Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia , 2012, Nature Genetics.

[31]  R. Reed,et al.  Initial splice-site recognition and pairing during pre-mRNA splicing. , 1996, Current opinion in genetics & development.

[32]  R. Reed,et al.  Phosphorylation of spliceosomal protein SAP 155 coupled with splicing catalysis. , 1998, Genes & development.

[33]  Or Gozani,et al.  A Potential Role for U2AF-SAP 155 Interactions in Recruiting U2 snRNP to the Branch Site , 1998, Molecular and Cellular Biology.

[34]  T. Maniatis,et al.  An extensive network of coupling among gene expression machines , 2002, Nature.

[35]  M. Stratton,et al.  Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. , 2011, The New England journal of medicine.

[36]  T. Owa,et al.  Splicing factor SF3b as a target of the antitumor natural product pladienolide , 2007, Nature Chemical Biology.

[37]  E. Giné,et al.  Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia , 2011, Nature Genetics.

[38]  M. Hagiwara,et al.  Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA , 2007, Nature Chemical Biology.

[39]  A. Jankowska,et al.  SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts , 2012, Leukemia.

[40]  A. Kohlmann,et al.  SF3B1 Mutations Have Adverse Impact On Time to Treatment Especially in Patients with 13q Deletions: A Study On 1,124 Chronic Lymphocytic Leukemia (CLL) Patients , 2012 .

[41]  A. McKenna,et al.  Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia , 2012, Cell.

[42]  G. Juliusson,et al.  NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia , 2013, Leukemia.

[43]  ONSTANZE,et al.  GENOMIC ABERRATIONS AND SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA , 2010 .

[44]  R. Dalla‐Favera,et al.  Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. , 2013, Blood.

[45]  A. Børresen-Dale,et al.  The Life History of 21 Breast Cancers , 2012, Cell.

[46]  J. Maciejewski,et al.  Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders , 2012, Leukemia.

[47]  L. Pasqualucci,et al.  Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. , 2011, Blood.

[48]  N. Schmitz,et al.  TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. , 2013, Blood.

[49]  Joshua F. McMichael,et al.  Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.

[50]  Jenny Taylor,et al.  Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. , 2012, Blood.